Analogues of the antibiotic thiolactomycin (TLM) have been synthesized and have been shown to have enhanced activity against whole cells of Mycobacterium tuberculosis H37Rv and against mycolic acid biosynthesis in cell extracts of Mycobacterium smegmatis. TLM has a methyl-branched butadienyl side chain attached at position 5 on a ' thiolactone ' ring, namely 4-hydroxy-3,5-dimethyl-5H-thiophen-2-one. Various combinations of strong bases were explored to create a reactive anion at position 5 on the thiolactone ring which could react with halides to produce 5-substituted derivatives ; the best reagent was two equivalents of lithium-bis-(trimethylsilyl)amide in tetrahydrofuran. The analogue with a 5-tetrahydrogeranyl substituent showed the best biological activity with an MIC 90 for M. tuberculosis of 29 µM and 92 % mycolate inhibition in extracts of M. smegmatis, as compared to 125 µM and 54 %, respectively, for TLM ; other related C 10 and C 15 isoprenoid derivatives had similar biological activity. These isoprenoid-based derivatives did not inhibit type II fatty acid synthase from M. smegmatis, but compounds with iso-butyl and iso-butenyl side chains did show some inhibitory activity against this enzyme. These short-chain derivatives did not inhibit mycolate synthesis or have significant antibiotic activity. Treatment of the thiolactone with a weaker base, sodium hydride in tetrahydrofuran, gave 3-alkyl-3,5-dimethyl-thiophene-2,4-dione analogues, which had no effect on fatty acid or mycolate synthesis. However, the geranyl derivative had an MIC 99 of 60 µM for M. tuberculosis, one quarter that (240 µM) of TLM, demonstrating its excellent antibiotic potential against an unknown cellular target.
INTRODUCTION
The structure and antibiotic properties of thiolactomycin (TLM) (1) were first reported by Oishi and coworkers Noto et al., 1982 ; Sasaki et al., 1982 ; Nawata et al., 1989) . TLM was the first example of a naturally occurring thiolactone to exhibit Abbreviations : cap film, capillary film ; EI, electron impact ; FAME, fatty acid methyl ester ; FAS-I, type I fatty acid synthase ; FAS-II, type II fatty acid synthase ; MAME, mycolic acid methyl ester ; THF, tetrahydrofuran ; TLM, thiolactomycin.
Details for the preparation of the thiolactomycin analogues shown in Table 1 are available as supplementary data in Microbiology Online (http ://mic.sgmjournals.org).
antibiotic activity. The compound has moderate in vitro activity against a broad spectrum of pathogens, including Gram-positive and Gram-negative bacteria (Noto et al., 1982 ; Hamada et al., 1990) and Mycobacterium tuberculosis (Slayden et al., 1996 ; Choi et al., 2000 ; Kremer et al., 2000) . TLM has also shown encouraging anti-malarial activity, involving inhibition of the type II fatty acid biosynthetic pathway in apicoplasts (Waller et al., 1998 ; Morita et al., 2000) . TLM has chemotherapeutic potential, as it is non-toxic to mice and affords significant protection against urinary tract and intraperitoneal bacterial infections (Miyakawa et al., 1982) . A series of 3-acetyl analogues of TLM have been prepared (Sakya et al., 2001) , with several having activity against Staphylococcus aureus and Pasteurella multocida.
Early studies showed that TLM activity was directed at type II fatty acid synthases (Hayashi et al., 1983 (Hayashi et al., , 1984 . The use of [1-"%C]acetate labelling in pea-leaf chloroplasts confirmed that TLM, and some of its analogues, inhibit type II dissociable fatty acid synthases (Jones et al., 1994 (Jones et al., , 2000 . Through the use of in vivo [1,2-"%C]acetate labelling of Mycobacterium smegmatis, TLM was shown to inhibit the biosynthesis of both fatty acids and mycolic acids (Slayden et al., 1996) , which are the characteristic major 2-alkyl-branched 3-hydroxy fatty acids in mycobacteria. Synthesis of the shorterchain mono-unsaturated αh-mycolates of M. smegmatis was not affected by TLM, but TLM did inhibit the synthesis of the longer chain di-unsaturated α-mycolates and epoxymycolates. The use of M. smegmatis cell extracts confirmed that TLM specifically inhibited the mycobacterial acylcarrier-protein-dependent type II fatty acid synthase (FAS-II), but it did not inhibit the multifunctional type I fatty acid synthase (FAS-I) (Slayden et al., 1996) . Analysis of the in vivo and in vitro data has suggested two separate sites of action for TLM : the β-ketoacylacyl carrier protein synthase in FAS-II and the elongation step involved in the synthesis of α-mycolates and oxygenated mycolates. In a recent study , it was shown that the enzymes targeted by TLM are KasA and KasB, which are involved in fatty acid and mycolic acid biosynthesis in M. tuberculosis. It was also indicated that a number of TLM analogues with different side chains in position 5 of the thiolactone ring also gave enhanced activity. This study presents details of the synthesis and additional properties of these and other analogues of TLM.
METHODS
Chemical methods and materials. "H and "$C NMR spectra (δ H and δ C chemical-shift data are expressed as p.p.m.) were recorded on Bruker WP 200 or WM 300-WB and JEOL Lambda 500 instruments. J values for coupling constants are in Hz ; singlets, doublets, triplets, quartets and multiplets are signified by s, d, t, q and m, respectively. Melting points (uncorrected) were determined on a Linkam HFS91 heating stage, using a TC92 controller ; recrystallization was not performed due to unusual difficulties for these compounds. Electron impact (EI) mass spectra were recorded on a Kratos MS80 RF spectrometer ; in certain cases only low-resolution molecular ions were recorded. Infra-red spectra (ν max in wave numbers ; s, m and w signify strong, medium and weak absorptions, respectively) were recorded as capillary films (cap films) or KBr discs on a Nicolet 20 SX FT-IR spectrometer. Elemental analyses were obtained on a Carlo-Erba Instrumentazione 1106 CHN analyser. TLC of thiolactonebased products used Merck 5554 silica gel aluminium sheets and chloroform, modified with 1-5 % methanol, as developing solvent (individual R F values not shown). After inspection under 254 nm UV light, analytical TLC sheets were sprayed with 5 % ethanolic molybdophosphoric acid, followed by charring at 180 mC. Flash column chromatography was carried out using Merck 7735 silica gel. Petrol refers to petroleum ether (b.p. 40-60 mC).
Chemical syntheses. The key intermediate thiolactone (2) (4-hydroxy-3,5-dimethyl-5H-thiophen-2-one) was prepared according to Wang & Salvino (1984) . Five different base treatments (Procedures A-E) were used to remove protons from the thiolactone (2), to add substituents at positions 3 or 5 of the thiolactone ring. These methods are exemplified in the following preparations ; additional compounds synthesized are shown in Table 1 and details of their preparation are available as supplementary data in Microbiology Online (http :\\mic.sgmjournals.org). TLM (1) was available from previous studies (Slayden et al., 1996 ; Kremer et al., 2000) .
According to Procedure A, thiolactone (2) (200 mg, 1n4 mmol) was dissolved in anhydrous tetrahydrofuran (THF) (10 ml) under nitrogen at 0 mC. In a separate flask, sodium hydride (70 mg, 3 mmol) was washed with dry hexanes (i3) and added in small portions to the thiolactone solution. After 30 min at 0 mC, the reaction was cooled to k78 mC followed by the drop-wise addition of t-butyllithium in hexanes (1n7 M, 820 µl, 1n4 mmol). After a further 30 min at k78 mC, transgeranyl bromide (300 µl, 1n5 mmol) in anhydrous THF (10 ml) was added drop-wise to the reaction mixture, which was then stirred at room temperature for 16 h. After 16 h, the reaction mixture was acidified with 2 M aqueous acetic acid and partitioned between brine (10 ml) and ethyl acetate (20 ml). The aqueous layer was re-extracted with ethyl acetate (2i20 ml), and the organic phases were combined, dried (MgSO % ) and reduced in vacuo to yield the crude product as a yellow oil. Flash column chromatography, eluting with chloroform, yielded the racemic title compound (85 mg, 22 % yield) as a yellow oil ; ν max (cap film)\cm − " 3393s, 1646s and 1080m ; δ H (300 MHz CDCl $ ) 1n59 (3H, s, 16-H or 17-H), 1n61 (3H, s, 16-H or 17-H), 1n63 (3H, s, 11-H), 1n66 (3H, s, 6-H), 1n75 (3H, s, 7-H), 1n99-2n03 (4H, m, 12-H and 13-H), 2n53-2n73 (2H, m, 8-H), 5n05-5n15 (2H, m, 9-H and 14-H) ; δ C (75n5 MHz CDCl $ ) 7n70 (C-6), 16n8, 17n9, 24n9, 25n9 and 37n4 (C-11, C-12, C-13, C-16 and C-17), 26n6 (C-7), 40n1 (C-8), 58n6 (C-5), 110n5 (C-3), 119n0 and 124n2 (C-10 and C-15), 131n9 and 140n3 (C-9 and C-14), 181n1 (C-4), 198n1 (C-2) ; m\z (low-resolution EI)
). An improved yield of the title compound was obtained by Procedure B. To a stirred solution of thiolactone (2) (50 mg, 0n35 mmol) in anhydrous THF (2 ml) at k78 mC under nitrogen, was added lithium bis(trimethylsilyl)amide, 20 % in THF (0n98 ml, 1n04 mmol). The reaction mixture was stirred for 30 min at k78 mC before the addition of geranyl bromide (0n21 ml, 1n04 mmol). The mixture was allowed to warm to room temperature and stirred for a further 3 h. It was then acidified with 2 M aqueous acetic acid and extracted into ethyl The biological data have been reported previously acetate. The organic layers were combined, washed with saturated brine solution, dried over MgSO % and reduced in vacuo to give the crude product as a yellow oil. Flash column chromatography, eluting with 2 % ethyl acetate in petrol, afforded the pure product as a yellow oil in a 53 % yield (52 mg) and with analytical data identical to that recorded above.
4-Hydroxy-3,5-dimethyl-5-octyl-5H-thiophene-2-one Following Procedure C, thiolactone (16) (250 mg, 1n7 mmol), t-butyllithium in hexanes (2n04 ml, 3n4 mmol) and 1-bromooctane (0n45 ml, 2n6 mmol) in anhydrous THF (10 ml) afforded the crude product as a yellow oil. Flash column chromatography, eluting with 5 % up to 20 % ethyl acetate in petrol (5 % increments), yielded the racemic title compound (110 mg, 22 % yield) as a sticky, yellow solid ; ν max (cap film)\cm − " 1611m and 1076s ; δ H (200 MHz CDCl $ ) 0n80 (t, J 6n6, 3H, 15-H), 1n10-1n41 (m, 12H, 9-H, 10-H, 11-H, 12-H, 13-H and
As the sole example of Procedure D, thiolactone (2) (310 mg, 2n2 mmol) was dissolved in anhydrous THF (10 ml) under nitrogen at k78 mC. Sodium bis-trimethylsilyl amide (1 M, 2n2 ml, 2n2 mmol) was added slowly to the mixture followed by the drop-wise addition of t-butyllithium in hexanes (1n7 M, 1n3 ml, 2n2 mmol). After stirring for 30 min at k78 mC, 1-bromo-3-methylbutane (290 µl, 2n4 mmol) was added dropwise to the reaction mixture, which was allowed to stir at room temperature for 16 h. The reaction mixture was then acidified with 2 M aqueous acetic acid and partitioned between saturated brine (10 ml) and ethyl acetate (20 ml). The aqueous layer was re-extracted with ethyl acetate (2i20 ml), and the organic phases were combined, dried (MgSO % ) and reduced in vacuo to yield the crude product as a yellow oil. Flash column chromatography, eluting with 10 % up to 50 % ethyl acetate in petrol (5 % increments), yielded the racemic title compound (270 mg, 57 % yield) as an off-white solid ; melting point 107-109 mC; ν max (KBr disc)\cm − " 1599s, 1092s ; δ H (200 MHz CDCl $ ) 0n89 (6H, d, J 6n5, 11-H and 12-H), 1n26-1n61 (5H, m, 8-H, 9-H and 10-H), 1n67 (3H, s, 6-H), 1n75 (3H, s, 7-H), 7n95 (1H, s, OH); δ C (125n7 MHz CDCl $ ) 7n5 (C-6), 22n5, 28n2 and 34n1 (C-9, C-10, C-11 and C-12), 26n0
3,3,5-Trimethyl-thiophene-2,4-dione According to Procedure E, thiolactone (2) (290 mg, 2 mmol) was dissolved in anhydrous THF (10 ml) under nitrogen at 0 mC. In a separate flask, sodium hydride (100 mg, 4 mmol) was washed with hexanes (i3) and added in small portions to the reaction mixture. The reaction mixture was stirred for 30 min before the drop-wise addition of iodomethane (140 µl, 2n2 mmol, 1n1 equiv.). The reaction was allowed to warm to room temperature and then heated under reflux for 1 h before being quenched with saturated aqueous NH % Cl (15 ml). The product was extracted with diethyl ether (3i30 ml), washed with water (30 ml), dried (MgSO % ) and reduced in vacuo to afford a crude yellow oil. Flash column chromatography, eluting with 5 % ethyl acetate in petrol, yielded the racemic title compound (120 mg, 37 % yield) as a yellow oil ; ν max (cap film)\cm − " 1734s, 1653s
Following General Procedure E, thiolactone (16) (250 mg, 1n7 mmol), sodium hydride (80 mg, 3n5 mmol) and transgeranyl bromide (380 µl, 1n9 mmol) in anhydrous THF (10 ml) afforded the crude product as a yellow oil. Flash column chromatography, eluting with 1 % diethyl ether in petrol, yielded a mixture of similar amounts of the two diastereoisomers of the title compound (360 mg, 74 % yield) as a yellow oil ; ν max (cap film)\cm − " 1746m, 1696w ; δ H (300 MHz CDCl $ ) 1n22 and 1n27 (3H, s, 6-H), 1n54-1n60 (m, 9H, 6H, 16-H and 17-H), 1n65-1n67 (3H, m, 11-H), 1n96-2n06 (4H, m, 12-H and 13-H), 2n54 (2H, m, 8-H), 4n16 and 4n27 (1H, q, J 8, 5-H), 5n19 (2H, m, 9-H and 14-H) ; δ C (125n7 MHz CDCl $ ) 16n3 and 16n4 plus 17n7 and 17n8 plus 17n9 and 18n0 plus 20n0 and 22n7 plus 25n9 and 25n9 (C-11, C-12, C-13, C-16 and C-17), 26n6 and 26n7 (C-7), 35n6 and 37n6 (C-6), 39n9 and 40n0 (C-8), 49n5 and 50n5 (C-3), 57n8 and 57n9 (C-5), 116n4 and 117n5 plus 124n0 and 124n1 (C-10 and C-15), 131n9 and 132n1 plus 140n5 and 141n3 (C-9 and C-14), 204n9 and 205n0 (C-4), 211n6 and 212n3 (C-2) ;
Determination of minimal inhibitory concentrations (MICs).
This was done by the following agar disc elution method. Cultures of M. tuberculosis H37Rv were diluted to 10$-10( bacteria ml − " and an aliquot (0n1 ml) of each dilution was grown on plates of 7H11 medium (Difco Laboratories) containing 10 % oleic acid\albumin\dextrose\catalase (OADC). Substrates were initially dissolved in ethanol and added to the medium to obtain concentrations of 15, 30, 60, 120, 240 and 480 µM. The plates were incubated at 37 mC for 21 days and the viable number of bacteria was determined by counting colonies. MICs were also defined as the lowest concentration of material required to produce 50, 90 or 99 % end-points in broth media.
Incorporation of [1,2-
14 C]acetate into fatty acids and mycolic acids. M. smegmatis was grown in a broth medium in 20 tubes to the mid-exponential phase, at which point TLM (75 µg ml − "), for example, was added to half of the tubes.
Further incubation followed at 37 mC for 1 h. Uniformly labelled [1,2-"%C]acetate (2n11 GBq mmol − " ; Amersham Biosciences) was added at 37 kBq mmol − " to both sets of tubes and they were further incubated at 37 mC, with gentle agitation, for 16 h. The "%C-labelled cells were harvested by centrifugation at 2000 g and washed twice with 0n9 % aqueous sodium chloride and once with water.
Effects of substrates on fatty acid and mycolic acid metabolism. One set of "%C-labelled control and substrate-treated cells, for example, was subjected to alkaline hydrolysis in 15 % aqueous tetrabutylammonium hydroxide at 100 mC overnight followed, after cooling to room temperature, by the addition of 2 ml CH # Cl # and 100 µl CH $ I. The entire reaction mixture was mixed on a shaking table for 30 min, centrifuged and the upper aqueous phase discarded. The lower organic phase was washed with 10 % aqueous HCl followed by water ; it was then dried. A known aliquot ("100 000 c.p.m.) of the resultant mixture of fatty acid methyl esters (FAMEs) and α-, αh-and epoxy-mycolic acid methyl esters (MAMEs) was analysed by TLC (Merck 5737 silica gel 60F254), developing twice in petroleum ether\acetone (95 : 5). Autoradiograms of the TLC plates were produced by overnight exposure of the plates to Kodak X-Omat AR film at k70 mC. This revealed the "%C-labelled FAMEs (R F 0n9) and α-, αh-and epoxy-MAMEs (R F 0n4-0n5), which were counted directly to estimate the total synthesis and the degree of inhibition of synthesis of FAMEs and MAMEs.
Preparation of soluble cytosolic and particulate cell-wall fractions. M. smegmatis (30 g, wet wt) was washed and resuspended in a buffer (30 ml) containing 100 mM potassium phosphate (pH 7n0), 1 mM EDTA, 5 mM DTT, 5 mM MgCl # and 2 mM PMSF at 4 mC and subjected to probe sonication for 10 min in 10i60 s pulses with 90 s cooling intervals between pulses. The sonicate was centrifuged at 27 000 g for 30 min at 4 mC and the supernatant was centrifuged at 100 000 g for 1 h to yield the soluble pale-yellow enzyme fraction, with a typical protein concentration of 8-10 mg ml − " and containing FAS-I and FAS-II enzyme activities. The particulate (P60) cell-wall enzyme fraction with mycolate-synthesizing activity was prepared as described previously (Wheeler et al., 1993a) .
Assays for FAS-I, FAS-II and mycolate-synthesizing activities.
The standard reaction mixture for the incorporation of radioactivity from [2-"%C]malonyl-CoA (1n887 GBq mmol − " ; NEN Life Science Products) into C "' and C #% fatty acids catalysed by FAS-I was composed as follows ; 100 mM potassium phosphate (pH 7n0), 5 mM EDTA, 5 mM DTT, 300 µM acetyl-CoA, 100 µM NADPH, 100 µM NADH, 1 µM FMN, 500 µM α-cyclodextrin, 20 µM malonyl-CoA, 100 000 c.p.m. of [2-"%C]malonyl-CoA and 100 µl of the cytosolic enzyme preparation (1-2 mg of protein) in a total volume of 500 µl. Similarly, the standard reaction mixture for the incorporation of radioactivity from [2-"%C]malonyl-CoA into C #% to C $# fatty acids catalysed by FAS-II contained the following ; 100 mM potassium phosphate (pH 7n0), 5 mM EDTA, 5 mM DTT, 100 µM palmitoyl-CoA, 140 µM NADPH, 140 µM NADH, 180 µg acyl carrier protein (ACP), 40 µM malonyl-CoA, 200 000 c.p.m. of [2-"%C]malonyl-CoA and 100 µl of the cytosolic enzyme preparation (1-2 mg of protein) in a total volume of 500 µl. For both assays, TLM (200 µM) was mixed, as were the other analogues, with the other assay components prior to the addition of protein. In both the FAS-I and the FAS-II assay, reactions were terminated by the addition of 500 µl of 20 % potassium hydroxide in 50 % methanol at 100 mC for 30 min. Following acidification with 300 µl of 6 M HCl, the resultant "%C-labelled fatty acids were extracted three times with petroleum ether. The organic extracts from both assays were pooled, washed once with an equal volume of water and dried in a scintillation vial prior to counting. It should be noted that FAS-II activity was identified as the label that appeared in all fatty acids, as a result of adding palmitoyl-CoA to the assay system ; individual products were not identified.
Incubations utilizing the mycolate-synthesizing P60 cell-wall fraction were performed as described by Wheeler et al. (1993a) . The reaction mixture contained 50 mM potassium phosphate (pH 6n0), 10 mM KHCO $ , 37 kBq of [1,2-"%C]acetate and 440 µl of the P60 preparation (2n0-3n5 mg of protein) in a total volume of 1 ml. TLM (200 µM) was mixed, as were the other analogues, with the other assay components prior to the addition of protein. Reaction mixtures, which were prepared in quadruplicate at each concentration, were incubated at 37 mC for 1 h. Reactions were terminated by the addition of 2 ml of 15 % aqueous tetrabutylammonium hydroxide to the reaction mixtures ; the corresponding FAMEs and MAMEs were isolated and counted as described previously.
RESULTS AND DISCUSSION

Chemical synthetic strategy
The key intermediate thiolactone (2) was prepared according to Wang & Salvino (1984) and converted into a variety of derivatives. If the thiolactone (2) is treated with basic reagents, either one or two protons can be abstracted, as shown in the scheme in Fig. 1 . A relatively moderate base, such as sodium hydride (Procedure E), removes only the enol proton, resulting in alkylation at ring position 3 on treatment with an alkyl halide (RX). Very strong bases (Procedures A-D) will remove an additional proton from position 5 of the thiolactone ring, and this more reactive anionic centre in the dianion 
Fig. 1.
Scheme showing the base-catalysed alkylation of thiolactone (2). In step (i), a relatively mild base (e.g. NaH) removes the enol proton to give an enolate ion, which can react with halides in step (ii) to give 3-substituted 3,5-dimethylthiophene-2,4-diones. In step (iii), stronger bases (e.g. BuLi) will remove an additional proton from the enolate anion, at position 5, giving a dianion that can be alkylated as in step (iv).
reacts preferentially with an RX to give 5-substituted derivatives (scheme in Fig. 1) . A chiral synthesis of TLM was reported by Chambers & Thomas (1997) .
Comparison of synthetic procedures for analogues substituted at position 4 on the thiolactone ring Wang & Salvino (1984) produced the dianion by treating the thiolactone intermediate (2) with 1 equiv. of sodium hydride at 0 mC in 1 : 1 THF\hexamethylphosphoramide (HMPA), followed by 1 equiv. of n-butyl lithium at k20 mC. The necessity of using the potent carcinogen HMPA to produce the dianion was undesirable, so alternative ways of producing it were investigated. The first method (Procedure A) used THF solvent, with sodium hydride removing the enol proton assisted by t-butyl lithium to create the dianion (scheme in Fig. 1 ). This strategy proved effective in the synthesis of a number of analogues, but yields were disappointing (11-33 %, compounds 3 and 6-10 ; Table 1 ). Consequently, the more straightforward use of 2 equivs of t-butyl lithium in THF (Procedure C) to produce the dianion was explored, but the yield (22 %) for compound (4) was poor (Table 1 ). In one experiment for the production of the dianion from the thiolactone intermediate (2), a better combination appeared to be 1 equiv. of sodium-bis-(trimethylsilyl)amide (1 M in THF) and 1 equiv. of t-butyl lithium (Procedure D), producing a respectable yield (57 %, compound 5 ; Table 1 ). Subsequently, it was found that 2 equivs of lithium-bis-(trimethylsilyl)amide in THF (Procedure B) was very convenient for this alkylation step, as demonstrated for an alternative preparation of compound (3) (53 %, Table 1 ).
Effect of 5-substituted analogues on mycolate synthesis in M. smegmatis
Analogues of TLM, substituted at position 5 of the thiolactone ring, were assayed for their inhibition of mycolic acid biosynthesis in preparations of cell-wall material from M. smegmatis, prepared according to an established procedure (Wheeler et al., 1993a) . TLM and its analogues were assayed at a concentration of 200 µM and each experiment was repeated four times. On completion of the experiments, a combination of TLC and autoradiography was used to reveal the "%C-labelled FAMEs and MAMEs ; these were counted directly to estimate the total synthesis and the degree of inhibition of synthesis of FAMEs and MAMEs. The values for the percentage inhibition of mycolic acid biosynthesis are shown in Table 1 .
The 3-methyl-2-butenyl side chain (6) offered 51 % inhibition of the synthesis of FAMEs and MAMEs, compared to an inhibition of 54 % for TLM (1). An inhibition of 80 % of the synthesis of these esters was observed for the trans-geranyl (3) and the trans-transfarnesyl analogue (7). Saturating one double bond of the trans-geranyl side chain (8) increases inhibitory activity further (93 %), as does saturating both of the double bonds (9) (92 %). Decreasing the length of the side chain to a 3-methylbutyl group (5) reduces inhibitory activity considerably (45 %), as does the introduction of a 3-methylbenzophenone side chain (10) at position 5 of the ring (21 %). However, the benzophenone analogue is considered active enough for possible photoaffinity labelling investigations (Prestwich et al., 1997) . The analogue with the octyl side chain (4) was made to investigate the importance of the C-3 methyl branch, as it had been reported previously (Jones et al., 1994 (Jones et al., , 2000 to have activity in pea extracts.
Effect of 5-substituted analogues on FAS-II from M. smegmatis
The effect of TLM analogues on mycobacterial FAS-II activity was studied in extracts of M. smegmatis. Details of the standard reaction mixture for incorporation of radioactivity from [2-"%C]malonyl-CoA into C #% to C $! fatty acids, catalysed by FAS-II, can be found in Methods. The reactions were performed in triplicate at concentrations of 1n0 mM substrate ; the corresponding FAMEs and MAMEs were isolated and counted as described earlier. The more hydrophobic compounds with the longer side chains (compounds 3 and 7-9 ; Table 1) were completely inactive against FAS-II. The shorter-chain analogues (compounds 5 and 6), by contrast, did show activity against FAS-II.
Activity of 5-substituted compounds against M. tuberculosis H37Rv
MIC &! and MIC *! values for the analogues against M. tuberculosis H37Rv were determined (Table 1) . Compared to TLM (1), the two four-carbon side-chain analogues (compounds 5 and 6) had much reduced activity against M. tuberculosis H37Rv (Table 1) . The trans-geranyl analogue (compound 3) appears to be relatively inactive against the bacterium, but sequential saturation of one (8) or two (9) double bonds gives good activity (Table 1) . Increasing the length of the side chain to trans-trans-farnesyl (7) also gives enhanced activity (Table 1) . The benzophenone analogue (10) has activity equal to that shown for TLM (1) ( Table 1) .
Structure-activity conclusions for 5-substituted analogues
According to studies on the interaction of TLM with FAS-IIs from E. coli, TLM binds reversibly to the active sites of FabB, FabF and FabH Price et al., 2001 ). This inhibition is competitive for malonyl acyl carrier protein but not for acetyl-CoA, suggesting that TLM mimics the binding of the former. Specifically, the crystal structure of the FabB\TLM adduct shows key binding of the carbonyl oxygen, at position 2 (1), with the two catalytic histidines and water-assisted hydrogen bonding of the enol group, at position 4, to amino acid residues 270 and 305. The thiolactone sulfur does not make any specific contacts. The two ring methyl group substituents, at positions 3 and 5, are accommodated in respective hydrophobic pockets formed from Phe229\Phe392 and Pro272\390. The unsaturated side chain, at position 5, specifically fits into a crevice between the two peptide bonds linking residues 391-392 and 271-272.
The present results (Table 1) show that modifications of TLM can provide analogues with enhanced activity against M. tuberculosis H37Rv and mycolic acid synthases from M. smegmatis ; no analogues had increased activity against FAS-II in the latter species. The M. smegmatis FAS-II enzyme system may be the mycobacterial synthase most analogous to the E. coli type II enzyme described above Price et al., 2001) . It was argued that the planarity of the side chain in TLM (1) might be an important contributing factor for successful binding. This hypothesis is supported by the finding that for the only two TLM analogues (5 and 6) with any anti-FAS-II activity (Table 1 ) the most active (6) has a double bond. It is also notable that these two TLM analogues (5 and 6) have branched four-carbon side chains, as in TLM (1). Perhaps the mycobacterial FAS-II enzyme is more restricted beyond any binding cleft than that in the Pisum sativum type II synthase, against which TLM analogue (3) was particularly active (Jones et al., 1994 (Jones et al., , 2000 .
The P60 (particulate) cellular preparation from M. smegmatis, prepared according to Wheeler et al. (1993a) , is a proven way of assessing mycolate biosynthesis in the presence of inhibitors that might be degraded by intact organisms or which might not gain ready access to the biosynthetic site. This was demonstrated very effectively by the specific inhibition of the mycolate ∆-5 desaturase by extremely labile cyclopropene fatty acids (Wheeler et al., 1993b) . The two TLM analogues with branched four-carbon side chains (5 and 6) had comparable activity to TLM (1), with the presence of the double bond in (6) again appearing to be beneficial (Table 1) . Therefore, analogue (6) appears to be a good surrogate for TLM (1) in studies of mycolate biosynthesis. The two fully trans unsaturated isoprenoid TLM analogues, with geranyl (3) and farnesyl (7) substituents, had essentially the same 80 % inhibitory effect, showing that an additional five-carbon unit was unimportant (Table 1 ). In comparison with the geranyl analogue (3), saturation of one (dihydrogeranyl) (8) or both (tetrahydrogeranyl) (9) of the double bonds raises mycolate inhibition to over 90 % (Table 1) , strongly suggesting that unsaturation is unnecessary in the side chain. The TLM analogue with a benzophenone substituent (10) has sufficient anti-mycolate activity to allow its possible use as a photo-activated probe for the enzyme site, according to previous guidelines (Prestwich et al., 1997) . The positive activity of (10) also shows that aromatic rings can be tolerated in the enzyme active site.
Interesting trends can also be discerned in the activity of the 5-substituted TLM analogues against M. tuberculosis H37Rv (Table 1) . It is reasonable to assume that the prime site of mycobactericidal action remains mycolate synthesis, but additional factors must include cell-envelope permeability and degradative enzymes. The two TLM analogues (5) and (6) have little activity (Table 1 ) compared to TLM (1). As compounds (1), (5) and (6) have five-carbon 5-substituents, it is likely that cell-envelope penetration by these compounds is comparable. It can be speculated that the terminal double bond and perhaps the double bond conjugation in TLM (1) is less attractive to degradative enzymes than the exposed methyl groups in analogues (5) and (6). Such a hypothesis is perhaps not supported by the analogues with 10-carbon side chains (3, 8 and 9), though such generalizations are impossible without precise knowledge of the exact metabolic pathways for each compound. Compounds (3), (8) and (9) should be readily assimilated by M. tuberculosis, but the anti-mycobacterial activity increases with decreased unsaturation of the side chain ; potent activity is given by the tetrahydrogeranyl compound (9) ( Table 1) . However, increased saturation of the side chain is not the only factor governing activity, as the farnesyl derivative (7) also shows excellent potency (Table 1) . It is possible that the 15-carbon side chain in (7) allows enhanced delivery of the compound to the active site, overriding possible increased susceptibility to degradation as possibly shown by the geranyl derivative (3). In retrospect, it might have been very informative to prepare and test an analogue of (7) with a saturated 15-carbon isoprenoid 5-substituent. The benzophenone analogue of TLM (10) is as good an antibiotic against M. tuberculosis H37Rv as TLM (1) ( Table 1) . Since the activity of (10) against mycolate synthesis is roughly half that of TLM (1) ( Table 1) , it is likely that increased cell-envelope permeability and chemical stability are compensatory factors. This latter result indicates that the preparation and analysis of a range of TLM analogues with aromatic substituents at position 5 might be rewarding.
The findings summarized above show that some TLM analogues have activity profiles that are distinct from TLM itself. TLM (1) appears to be a general inhibitor of type II fatty acid condensing enzymes (e.g. FAS-II and mycolate synthases) but the analogues with longer side chains (3 and 7-9) inhibit mycolate synthases more strongly than TLM (1) and actually stimulate FAS-II (Table 1) . Detailed knowledge of the individual enzymes will be necessary to provide an explanation of these facts. It proved impossible to evaluate the activity of the 5-octyl TLM analogue (4) ( Table 1) to ascertain the necessity for chain branching. However, in studies on pea-leaf chloroplasts (Jones et al., 1994 (Jones et al., , 2000 , it was found that TLM analogue (4) had similar activity to the geranyl derivative (3), suggesting that branching is not too important for activity.
In a previous study, Slayden et al. (1996) showed that TLM allows the synthesis of "60-carbon monounsaturated αh-mycolates in M. smegmatis, but inhibits the synthesis of "70-80-carbon di-unsaturated α-mycolates in this organism. (Minnikin et al., 1982) . Therefore, it could be of immediate value to carry out a detailed study of the effect of TLM and its analogues (Table 1) on mycolic acid synthesis in M. chelonae.
Synthesis and activity of ketothiolactone analogues alkylated at position 3
The 3-alkylated 4-ketothiolactone analogues (11 and 12 ; Table 2 ) were synthesized by the addition of 1 equiv. of sodium hydride to thiolactone (2), followed by an alkyl iodide (see scheme in Fig. 1 ). The ketothiolactone analogues were assayed for their activity against mycolic acid biosynthesis and FAS-II in extracts from M. smegmatis (Table 2) . MIC ** values for these compounds against M. tuberculosis H37Rv are also reported ( Table 2 ).
The ketothiolactone analogues (11 and 12) appear to be inactive against both mycolic acid biosynthesis and FAS-II, but they have promising effects against M. tuberculosis H37Rv. The methyl analogue (11) had an MIC ** value equivalent to that of TLM (1) (240 µM). The more hydrophobic ketothiolactone (12), with a trans-geranyl group, had increased activity, as shown by an MIC ** value of 60 µM ( Table 2 ). The anti-mycobacterial activity of TLM analogue (12) ( Table 2) is, therefore, similar to that of analogues (7) and (9) ( Table 1 ). The site of action of TLM analogues (11) and (12) remains to be pinpointed, but potential new antibiotic principles have been highlighted by these compounds.
Conclusions
The principle that analogues of TLM (1) might have enhanced activity against FAS-IIs was established by Jones et al. (1994 Jones et al. ( , 2000 . In particular, it was found that the TLM analogue with a 5-geranyl substituent (3) showed greatly enhanced inhibition of fatty acid condensing enzymes in pea-leaf chloroplasts. The chemical syntheses of the analogues studied by Jones et al. (1994 Jones et al. ( , 2000 were not reported ; hence, the study presented here describes the development of the necessary synthetic procedures for a range of such TLM analogues. The essential biological activity of the majority of the 5-substituted TLM analogues (3 and 5-10 ; Table 1 ) has been reported previously , but with limited interpretation. The novel 3-substituted TLM analogues (11 and 12) (Table 2) are reported for the first time.
TLM (1) is an important anti-microbial agent of great utility in studies of fatty acid biosynthesis . Its synthesis is not facile, however, and some of the TLM analogues (Table 1) can be recommended as more accessible surrogates. As an agent against M. tuberculosis and an inhibitor of mycolic acid synthesis, the fully saturated tetrahydrogeranyl analogue (9) recommends itself (Table 1) ; the lack of side chain double bonds in this agent should enhance its chemical stability. TLM remains the best inhibitor of mycobacterial FAS-II condensing enzymes, but the iso-pentenyl analogue (6) would be a more accessible alternative. The new antibiotic principles embodied in derivatives (11) and (12) should be explored.
